ArticleRegenerative medicine2025
Effect of mesenchymal stem cell conditioned medium on hepatocyte matrix implant to alleviate liver cirrhosis in rats.
Article in Regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocyte transplantation has gained importance as an alternative treatment to orthotopic liver transplantation for end-stage liver disease. This study explores the modification of the hepatocyte matrix implant (HMI) procedure by replacing islet cells with conditioned medium (CM) derived from human umbilical cord-MSC (hUC-MSC) supplementation to alleviate liver cirrhosis in a rat model.
methodsThe male Sprague Dawley rats were induced liver cirrhosis using thioacetamide for 11 weeks, and implanted with matrices on the small bowel mesentery, according to the groups. Four groups were assessed: blank matrix (cell-free), hepatocytes seeded-matrix (Hep), hepatocytes+islets co-seeded-matrix (Hep:Islet), and hepatocytes seeded-matrix supplemented with CM (Hep+CM).
results
conclusionThese findings suggest that CM can effectively replace islet in supporting hepatocyte proliferation and function, enhancing the therapeutic potential of HMI procedure. No writing assistance was utilized in the production of this manuscript or liver cirrhosis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.